Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aragon Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
University of Wisconsin, Madison
Exelixis
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Takeda
City of Hope Medical Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Eli Lilly and Company